Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
NextCure ( (NXTC) ) has shared an announcement.
On December 19, 2025, NextCure, Inc. entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, allowing the company to sell up to $14.5 million of its common stock from time to time through the agent on Nasdaq or other permitted markets at prevailing or negotiated prices, with the agent earning a 3% commission on gross proceeds. The company plans to use any net proceeds for general corporate purposes and working capital, including funding preclinical studies, clinical trials and advancement of its product candidates, a move that could bolster its R&D pipeline and operational flexibility, while customary indemnification and legal opinions have been put in place to support the offering structure.
The most recent analyst rating on (NXTC) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on NextCure stock, see the NXTC Stock Forecast page.
Spark’s Take on NXTC Stock
According to Spark, TipRanks’ AI Analyst, NXTC is a Underperform.
NextCure’s overall stock score reflects significant financial challenges, including a lack of revenue and ongoing cash burn typical of early-stage biotech firms. The technical analysis suggests a bearish trend with potential volatility, while valuation metrics are unfavorable due to negative earnings. Despite a positive corporate event related to clinical trials, the company must urgently address its financial sustainability through partnerships or additional funding to enhance its long-term prospects.
To see Spark’s full report on NXTC stock, click here.
More about NextCure
NextCure, Inc. is a biotechnology company focused on developing product candidates supported by preclinical studies and clinical trials, indicating a primary focus on biopharmaceutical research and development within the healthcare sector.
Average Trading Volume: 54,591
Technical Sentiment Signal: Hold
Current Market Cap: $54.69M
Learn more about NXTC stock on TipRanks’ Stock Analysis page.